The overall aim is to develop and preclinically validate novel therapies for patients at diagnosis and following relapse. Therefore specific aims are to:
- Determine preclinical efficacy of novel drugs and combinations in models of AML
- Develop novel ROS diagnostic techniques to guide treatment selection
- Track changes in signalling in patients refractory to chemotherapies and targeted therapies
This funding will specifically contribute to AIM 3.